Immunohistochemical detection of HSP27 and hnRNP K as prognostic and predictive biomarkers for colorectal cancer

Medical Oncology

Volumn 29, Issue 3, 2012, Pages 1780-1788

  Wang, Feng ^a   Zhang, Peng ^a   Shi, Chenzhang ^a   Yang, Yongzhi ^a   Qin, Huanlong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Colorectal cancer; Heat shock protein 27 (HSP27); Heterogeneous nuclear ribonucleoprotein K (hnRNP K); Immunohistochemistry; Prognosis; Tissue microarray

Indexed keywords

FLUOROURACIL; HEAT SHOCK PROTEIN 27; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; TUMOR MARKER;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

COLORECTAL NEOPLASMS; FEMALE; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN K; HSP27 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872799855     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0037-3     Document Type: Article

References (38)

1. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectalcancer. CA Cancer J Clin. 2009;59:366-78.
2. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American joint committee on cancer sixth edition staging. J Natl Cancer Inst. 2004;96:1420-5.
3. Celis JE, Gromov P. Proteomics in translational cancer research: toward an integrated approach. Cancer Cell. 2003;3:9-15.
4. Eschrich S, Yang I, Bloom G, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol. 2005;23:3526-35.
5. Kim IJ, Lim SB, Kang HC, et al. Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer. Dis Colon Rectum. 2007;50:1342-53.
6. Battifora H, Mehta P. The checkerboard tissue block. An improved multitissue control block. Lab Invest. 1990;63:722-4.
7. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844-7.
8. Rosen DG, Huang X, Deavers MT, et al. Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol. 2004;17:790-7.
9. Kleiner HE, Krishnan P, Tubbs J, et al. Tissue microarray analysis of eIF4E and its downstream effector proteins in human breast cancer. J Exp Clin Cancer Res. 2009;28:5.
10. Zhang P, Huang L, Ma YL, et al. HnRNP K and PDI marked response to chemotherapy to human colorectal cancer cells. Electrophoresis. 2010;31:1731-8.
11. Liu W, Ma Y, Huang L, et al. Identification of HSP27 as a potential tumor marker for colorectal cancer by the two-dimensional polyacrylamide gel electrophoresis. Mol Biol Rep. 2010;37:3207-16.
12. Walter SD, Feinstein AR, Wells CK. A comparison of multivariable mathematical methods for predicting survival-II. Statistical selection of prognostic variables. J Clin Epidemiol. 1990;43:349-59.
13. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 2005;10:86-103.
14. Kurahashi T, Miyake H, Hara I, Fujisawa M. Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. J Urol. 2007;177:757-61.
15. Foster CS, Dodson AR, Ambroisine L, et al. Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement. Br J Cancer. 2009;101: 1137-44.
16. Geisler JP, Tammela JE, Manahan KJ, et al. HSP27 in patients with ovarian carcinoma: still an independent prognostic indicator at 60 months follow-up. Eur J Gynaecol Oncol. 2004;25:165-8.
17. Kapranos N, Kominea A, Konstantinopoulos PA, et al. Expression of the 27-kDa heat shock protein (HSP27) in gastric carcinomas and adjacent normal, metaplastic, and dysplastic gastric mucosa, and its prognostic significance. J Cancer Res Clin Oncol. 2002;128:426-32.
18. Feng JT, Liu YK, Song HY, et al. Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Proteomics. 2005;5:4581-8.
19. Geisler JP, Geisler HE, Tammela J, et al. A study of heat shock protein 27 in endometrial carcinoma. Gynecol Oncol. 1999;72: 347-50.
20. Nakajima M, Kuwano H, Miyazaki T, et al. Significant correlation between expression of heat shock proteins 27, 70 and lymphocyte infiltration in esophageal squamous cell carcinoma. Cancer Lett. 2002;178:99-106.
21. Wang A, Liu X, Sheng S, et al. Dysregulation of heat shock protein 27 expression in oral tongue squamous cell carcinoma. BMC Cancer 2009;9:167.
22. Pei H, Zhu H, Zeng S, et al. Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer. J Proteome Res. 2007;6:2495-501.
23. Zhao L, Liu L, Wang S, et al. Differential proteomic analysis of human colorectal carcinoma cell lines metastasis-associated proteins. J Cancer Res Clin Oncol. 2007;133:771-82.
24. Tweedle EM, Khattak I, Ang CW, et al. Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer. Gut. 2010;59:1501-10.
25. Frattini M, Balestra D, Suardi S, et al. Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res. 2004;10:4015-21.
26. Dreyfuss G, Matunis MJ, Pinol-Roma S, Burd CG. hnRNP proteins and the biogenesis of mRNA. Annu Rev Biochem. 1993; 62:289-321.
27. He Y, Smith R. Nuclear functions of heterogeneous nuclear ribonucleoproteins A/B. Cell Mol Life Sci. 2009;66:1239-56.
28. Bomsztyk K, Denisenko O, Ostrowski J. hnRNP K: one protein multiple processes. Bioessays. 2004;26:629-38.
29. Carpenter B, McKay M, Dundas SR, et al. Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br J Cancer. 2006;95:921-7.
30. Klimek-Tomczak K, Mikula M, Dzwonek A, et al. Editing of hnRNP K protein mRNA in colorectal adenocarcinoma and surrounding mucosa. Br J Cancer. 2006;94:586-92.
31. Hope NR, Murray GI. The expression profile of RNA-binding proteins in primary and metastatic colorectal cancer: relationship of heterogeneous nuclear ribonucleoproteins with prognosis. Hum Pathol. 2011;42:393-402.
32. Evans JR, Mitchell SA, Spriggs KA, et al. Members of the poly (rC) binding protein family stimulate the activity of the c-myc internal ribosome entry segment in vitro and in vivo. Oncogene. 2003;22:8012-20.
33. Lee PT, Liao PC, Chang WC, Tseng JT. Epidermal growth factor increases the interaction between nucleolin and heterogeneous nuclear ribonucleoprotein K/poly(C) binding protein 1 complex to regulate the gastrin mRNA turnover. Mol Biol Cell. 2007;18:5004-13.
34. Notari M, Neviani P, Santhanam R, et al. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood. 2006;107:2507-16.
35. Inoue A, Sawata SY, Taira K, Wadhwa R. Loss-of-function screening by randomized intracellular antibodies: identification of hnRNP-K as a potential target for metastasis. Proc Natl Acad Sci USA. 2007;104:8983-8.
36. Neo JC, Rose P, Ong CN, Chung MC. Beta-Phenylethyl isothiocyanate mediated apoptosis: a proteomic investigation of early apoptotic protein changes. Proteomics. 2005;5:1075-82.
37. Rose P, Armstrong JS, Chua YL, et al. Beta-phenylethyl isothiocyanate mediated apoptosis; contribution of Bax and the mitochondrial death pathway. Int J Biochem Cell Biol. 2005;37: 100-19.
38. Rahman-Roblick R, Roblick UJ, Hellman U, et al. p53 targets identified by protein expression profiling. Proc Natl Acad Sci USA. 2007;104:5401-6.